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Full Research Paper

Research on the Competitiveness and Trade Potential of China-India
Pharmaceutical Trade under the One Belt and One Road Initiative
Lin Ni 1 ，Shihui Shuai 2，Wei Li 1
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School of Economics and Management, China University of Geosciences, Wuhan, 430074, China
一

2

School of English and International Studies, Beijing Foreign Studies University, Beijing, 100089, China

Abstract: The implementation of "One Belt And One Road" initiative brings both opportunities and challenges for China to
strengthen the pharmaceutical trade cooperation with India. Based on the data of pharmaceutical products trade from 2001 to
2018, this paper examines the pharmaceutical trade competition between China and India, establishes an expanded trade
gravity model between China and countries along the "One Belt And One Road" Initiative, and measures the export potential
of Chinese pharmaceutical products to India. The results show that China's pharmaceutical trade volume to India is
positively affected by GDP of the two countries, Indian population and language, and negatively affected by distance.
China's pharmaceutical export trade potential to India as a whole belongs to "potential reshape" type. It is urgent need for the
two countries to further strengthen trade cooperation in pharmaceutical products in the context of the global spread of
Covid-19 pandemic. Finally, the countermeasures and suggestions to promote the development of China-India
pharmaceutical trade are put forward.

Keywords：India, pharmaceutical products, gravity model, co-integration test, trade potential
1. INTRODUCTION
In recent years, the "One Belt And One Road" health cooperation and efforts to create the "Health Silk
Road" have strongly promoted the development of the pharmaceutical industry in relevant countries. With the
worldwide pandemic of the CoviD-19 epidemic, the international attention to public health and hygiene and the
development of pharmaceutical trade will be promoted. China and India are both emerging economies in Asia.
The pharmaceutical industry of the two countries has entered the ranks of world powers in terms of
manufacturing capacity, and the pharmaceutical trade between the two countries is particularly prominent.
In recent years, domestic and foreign scholars have made many achievements in the study of
pharmaceutical trade and Cross-border E-commerce. Relevant literatures are summarized as follows: Regarding
China-India pharmaceutical trade, Mai Liyi (2018) compared the differences between China and India in the
internationalization mode of generic drugs industry, and summarized the enlightenment of the Indian
pharmaceutical internationalization mode to the internationalization of Chinese generic drugs[1]. Liu Shu (2018)
pointed out that the promotion of China-India pharmaceutical industry cooperation is inseparable from the joint
efforts of government departments, industrial chambers of commerce and pharmaceutical enterprises, and the
key is to select the right cooperation field and path[2]. Musadiq et al. (2018) pointed out that Indian traditional
medicine natural plant products have a high trade status at the global national and regional level through the
study of Indian traditional medicine market[3]. There has been a wealth of research on the impact of reviews
presented on e-commerce platforms on consumers' cognitive and behavioral decisions[4-5]. Scholars have
basically reached a consensus on the positive promoting effect of perceived security on consumers' purchasing
behavior t[6]. Meskaran et al(2014). summarized the factors affecting consumers' perception of security in
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e-commerce transactions, and pointed out that e-commerce platform elements would have an impact on buying
intention through consumers' perception of security[7].Zhang Xiaheng(2017) believed that with cross-border
e-commerce spreading globally, India's cross-border e-commerce market is emerging. The development of
cross-border e-commerce in India is characterized by huge development potential, rapid growth rate, strong
mobile trend, and preference for working hours shopping and payment methods of cash on delivery[8]. Li
Zongwei et al.(2017) regarded that the transaction volume information of e-commerce platforms can convey
signals of group purchase and product identification to consumers, which improves consumers' perceived value
of products sold on e-commerce platforms[9]. Zhang Xiaodong(2018)found that logistics capability is an
important clue for consumers to identify cross-border e-commerce brands, and can help consumers form brand
preferences for cross-border e-commerce[10]. Existing research results show that there are few research results on
quantitative measurement of the trade competitiveness of Chinese and Indian pharmaceutical products, and the
analysis on the trade potential of Chinese pharmaceutical products exported to India is also relatively lacking.
Therefore, In this paper, theoretical analysis and empirical test are combined to analyze the competitiveness of
China-India pharmaceutical trade. Trade gravity model is used to analyze the influencing factors of China's
pharmaceutical exports to India based on panel data and to measure the trade potential. The research results are
helpful to clarify the influence mechanism of China-India pharmaceutical trade, enrich the theoretical analysis
framework of related research, and have positive significance for the construction of human health community.
At the same time, they can also provide empirical reference for promoting the development of China-India
pharmaceutical trade.
2. COMPETITIVENESS ANALYSIS OF CHINA-INDIA PHARMACEUTICAL TRADE
As a major country in the world in terms of the manufacturing capacity of the pharmaceutical industry, the
analysis of the competition between China and India in pharmaceutical trade can reveal the trade potential of
pharmaceutical products between China and India.
2.1 Classification of medicinal products
According to the characteristics of pharmaceutical products, based on the 4-digit HS code of
pharmaceutical products [International Convention for Harmonized Commodity Description and Coding System
(Harmonized System)], pharmaceutical products with the code of 30 are divided into the following six 4-digit
pharmaceutical products according to HS96, as shown in Table 1.
Table 1.Classification of pharmaceutical products under HS96 standard
The HS code

Category Product Name

3001

Extracts and products from human and animal tissues

3002

Biological products

3003

Western medicine raw materials

3004

Western medicine preparations

3005

Medical dressings

3006

Special medical supplies (including sterile suture materials, X-ray contrast agents,
medical boxes, etc.)

2.2 Competitiveness analysis of China-India pharmaceutical trade
The Revealed Comparative Advantage Index (RCA index) is defined as the ratio between the share of the
export volume of a certain commodity of a country in its total export volume and the share of the export volume
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of such commodity in the total world export volume. The calculation formula is as follows:

RCA ik  ( X ik / X i ) /( X wk / X w )

（1）

In the formula，RCAik represents the explicit comparative advantage index of Class k goods in Country i,
Xik represents the export volume of Class k products in Country i, and Xi represents the total export volume of
all products in Country i. Xwk represents the global exports of Class k products, and Xw represents the total
exports of all products in the world. If RCAik is less than 0.8, it means that country i has weak international
competitiveness in category k products. If 0.8 < RCAik < 1.25, it means that Country i has certain international
competitiveness in category k products. If 1.25 < RCAik < 2.5, it means that Country i has a strong international
competitiveness in category k products. If RCAik > 2.5, it means that Country i has a strong international
competitiveness in category k products [11].
The sample industries selected by China and India are shown in Table 2 and Table 3 for their displayed
comparative advantage index under the four-digit classification standard of International Trade Classification
(HS).
Table 2. RCA index of six pharmaceutical products in China from 2001 to 2018
3001

3002

3003

3004

3005

3006

2001

22.97

0.86

1.31

0.47

18.86

0.99

2002

26.29

8.07

0.88

0.44

22.52

1.76

2003

34.57

6.20

0.88

0.44

24.98

2.26

2004

40.13

3.57

0.82

0.44

27.93

2.63

2005

37.13

3.13

0.66

0.45

26.70

2.22

2006

30.13

4.73

1.02

0.46

28.18

3.48

2007

33.32

4.97

1.3

0.49

27.13

3.56

2008

32.34

4.07

1.46

0.47

25.55

3.69

2009

43.04

4.07

1.82

0.42

19.63

4.32

2010

37.40

3.96

3.47

0.38

17.11

3.55

2011

20.16

3.12

3.19

0.55

17.45

2.92

2012

19.48

4.15

3.81

0.61

16.92

3.28

2013

19.55

6.28

4.01

0.64

16.56

3.78

2014

19.67

8.51

3.84

0.67

16.25

4.25

2015

22.74

9.46

4.46

0.67

15.36

4.87

2016

23.89

17.77

4.56

0.67

14.63

5.07

2017

27.76

15.78

3.72

0.73

14.74

4.32

2018

25.84

13.69

3.06

0.79

13.36

3.60

It can be seen from Table 2 that from 2001 to 2018, China has strong international competitiveness in 3001,
3002, 3005 and 3006 pharmaceutical products. In 2010, the RCAik of category 3003 pharmaceutical products
exceeded 2.5, and it gradually became a strong international competitiveness. There are only a few of the 3,004
pharmaceutical products in China that have strong international competitiveness. Pharmaceutical products are
generally manufactured in two steps: the drug substance and the drug preparation. China has become the largest
producer and exporter of API in the world. In 2018, 80% of China's pharmaceutical exports were APIs, and the
largest buyer was India, where China acts as an upstream supplier.
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Table 3. RCA index of six pharmaceutical products in India from 2001 to 2018
3001

3002

3003

3004

3005

3006

2001

1.09

7.72

4.59

0.94

0.49

0.29

2002

1.08

9.87

2.71

0.97

0.48

0.32

2003

1.21

10.18

3.03

0.97

0.51

0.32

2004

1.12

10.21

2.86

1.01

0.42

0.40

2005

1.16

6.28

1.51

1.12

0.57

0.29

2006

0.26

11.95

1.92

1.07

0.55

0.25

2007

1.66

9.32

2.43

1.08

0.54

0.37

2008

0.70

3.77

2.57

1.10

0.45

0.32

2009

0.53

8.75

2.81

1.07

0.45

0.40

2010

0.20

3.45

4.37

1.14

0.59

0.38

2011

0.21

4.33

3.36

1.18

0.53

0.41

2012

0.39

4.42

2.72

1.24

0.27

0.45

2013

0.41

6.00

2.19

1.27

0.35

0.54

2014

0.44

7.16

1.62

1.31

0.31

0.73

2015

0.51

8.30

1.20

1.33

0.27

0.56

2016

0.60

10.69

1.26

1.34

0.26

0.56

2017

0.43

10.73

1.08

1.42

0.28

0.59

2018

0.42

10.10

0.84

1.47

0.29

0.52

The pharmaceutical industry is a pillar of India's economic development. India has helped upgrade the
industry with legal protections for generic drugs, one-stop shopping sites for drugs, and advanced business
models adopted by pharmaceutical retail chains. For example, some pharmaceutical retail chains combine basic
diagnostic functions of clinics with drug-testing services and even a service to transport patients, illustrating the
different cultures of pharmaceutical consumption in India and China. It can be seen from Table 3 that India has
strong international competitiveness in category 3002 pharmaceutical products, but there is not a big difference
in the explicit comparative advantage index between China and India in category 3002 pharmaceutical products.
India's international competitiveness in category 3003 pharmaceutical products has declined every year since
2011. In terms of category 3004 pharmaceutical products, the WTO gave India a transitional period of 10 years
to "protect pharmaceutical products" after its entry into the WTO. Indian pharmaceutical companies forced to
overtake by virtue of their institutional advantages. Up to now, India is undertaking preparations that China is
not qualified for, which is conducive to attracting foreign investment and exploring the international market. To
sum up, China and India should further strengthen pharmaceutical trade cooperation, scale production of
pharmaceutical products with strong international competitiveness, and increase the export of pharmaceutical
products with strong international competitiveness. To be specific, China should increase the export of 3001,
3003, 3005 and 3006 pharmaceutical products to India; At the same time, India should step up its export of 3004
categories of pharmaceutical products to China.
3. ANALYSIS ON THE TRADE POTENTIAL OF CHINESE PHARMACEUTICAL PRODUCTS
EXPORTED TO INDIA
In this paper, the gravity model is used to calculate and analyze the trade potential of Chinese
pharmaceutical products exported to India.
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3.1 Analysis on the influencing factors of Chinese pharmaceutical products export to India
3.1.1 Sample selection and data sources
In this paper, the selected 13 "One Belt And One Road" countries includes India, Egypt, Philippines,
Thailand, Vietnam, Pakistan, Turkey, Singapore, Poland, Russia, Malaysia, Bangladesh, Indonesia etc. The
reasons are as follows: first, China and these countries larger pharmaceutical trade, secondly, these countries
basically cover the major cooperative countries of ASEAN, West Asia, South Asia, CIS, Central and Eastern
Europe and North Africa along the "One Belt And One Road" route. Their economic, cultural, social systems
and living standards are different, which can better reflect the overall characteristics along the "One Belt And
One Road". Therefore, the selection of the above countries is very convincing for the estimation and analysis of
the trade potential of China's pharmaceutical exports to India. The export data of 30 categories of medicines
encoded in HS96 version is from Trade map database, the GDP and total population data of each country are
from World Development Indicator database of World Bank, and the geographical distance between China and
each country is from French Center for International Economic Research (CEPII).
3.1.2 Model setting and variable selection
Gravity model is an effective tool to study international trade problems. Combined with the actual research
content and the availability of data, this paper will use the logarithmic form of gravity model to explore the
influencing factors of Chinese pharmaceutical products export to India under the background of "One Belt And
One Road". The specific equation is as follows:

lnTijt  0  1 lnGDP
it  2 lnGDP
jt  B3 lnPOP
j  4 lnDISij  5FTA
ij  6LAN
ij  

（2）

In the formula, Tijt the explained variable, refers to the pharmaceutical product export volume between
China i and the trading country (or region) j, β0 represents the constant term, βk (k = 1,2... , 5) is the regression
coefficient of explanatory variables, μ represents the random error term, and the explanatory variables are as
follows:
(1) GDP

it

stands for China's gross domestic product. It reflects China's export supply capacity and also

indicates the economic development scale of a country or region. The larger the economic scale, the greater the
trade flow.
(2) GDP

jt

is the gross domestic product of importing country j. It reflects the demand capacity of the

importing country. The greater the GDP of the importing country, the greater the trade flow.
(3) POPj is the population of country j of the importing country. The greater the population, the greater the
need for imports.
(4) DISij represents the spherical distance between China and the capital of country j. The greater the
distance, the higher the transport costs, the less trade flows.
(5) FTAij indicates whether the two countries have a free trade agreement in force. Free trade agreements
reflect the level of regional integration and are represented by dummy variables. 1 indicates that they have
entered into force, otherwise 0 is set. The preferential policies of free trade agreements will reduce bilateral
trade barriers to some extent and increase trade flows.
(6) LANij expresses whether the two countries share a common language. Language affects communication
cost, which is represented by dummy variable. 1 means common language, otherwise 0. A smooth language can
eliminate more trade barriers, and a common language will promote the development of bilateral trade.
3.1.3 Unit root test
In order to verify the stationarity of the sequence, unit root test is carried out on each variable selected in this
paper. In this paper, LLC, IPS, ADF-Fisher and PP-Fisher tests were used to conduct unit root test for the
first-order difference of the original data of the explained variables and the main explanatory variables in the model.
According to the analysis of the test results, the original data of lnGDPit, lnGDPjt, lnPOPi, lnDISij, FTAij and LANij did
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not reject the null hypothesis of "unit root existence", which indicated that the original data was non-stationary.
Therefore, the unit root test of first-order difference was needed for lnGDPit, lnGDPjt, lnPOPi, lnDISij, FTAij and
LANij According to the test results, lnGDPit, lnGDPjt, lnPOPi passed 1% significance level test, lnDISij passed the
significance level test of 5% and 10%.Namely, both the first-order difference reject the null hypothesis and the data
are stable, but FTAij variable raw data and the first order difference are not rejected "unit root" null hypothesis,
indicates that the variable is not through stationarity test, thus eliminating the variable.
Table 4. Unit root test results
variable

LLC Inspection

IPS Inspection

ADF-Fisher Inspection

PP-Fisher Inspection

15.9231

30.8596*

LnGDPit

-2.8767***

-0.3221

D (LnGDPit)

-7.9931***

-3.6172***

40.9143***

71.9053***

LnGDPjt

-3.0708***

0.1227

13.8291

29.8140***

D(LnGDPjt)

-2.5208***

-3.2634***

21.6166***

39.1392***

LnPOPj

-3.7526***

-0.5987

24.3259

14.2423

D(LnPOPj)

-15.5064***

-2.4173***

43.8724***

25.2629***

LANij

-4.3182***

-1.1277

21.1132*

21.4461*

D(LANij)

-7.0317***

-1.8665***

48.4475***

57.6142***

LnDISij

-2.7301**

-0.2033

18.7535

25.1509**

D(LnDISij)

-3.7336***

-1.4077*

22.8182*

25.1563**

FTAij

0.0813

0.7081

5.1176

30.9358

D(FTAij)

-1.5708*

-0.7275

17.7621

52.0237***

Note: D in the table represents first-order difference. *, ** and *** indicate significant at the level of 10%,
5% and 1%, respectively.
3.1.4 Panel co-integration test
The co-integration test methods can be divided into two categories, one is Engle and Granger two-step test
including Pedroni test and Kao test, and the other is Johansen co-integration test. This paper mainly adopts Kao
test, and the test results are as follows:
Table 5. Co-integration test results
Inspection methods
Kao test

the null hypothesis

statistic

t-Statistic

Prob.

conclusion

no co-integration relationship

ADF

-3.3695***

0.0000

reject

3.1.5 Empirical results
After passing the stationarity test above, the variables that failed the test were deleted in this paper to get a
new gravity model. The regression results are shown in Table 6.
Table 6. Regression results of gravity model
Variable

Coefficient

T Statistics

P value

C

-11.25987

-14.49707

0.0000

lnGDPit

0.942061

14.66546

0.0000

lnGDPjt

0.570741

8.509772

0.0000

lnPOPi

0.125905

2.600167

0.0099

lnDISij

-0.677407

-4.575687

0.0000

LANij

0.312351

5.921334

0.0000

R2=0.791128

Adjusted R2=0.785607

F=143.2981 p=0.000000 DW=2.420551
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Data source: collated according to Eviews output
The regression results show that the determination coefficient of the regression equation R2 is 0.791128 and
the adjusted R2 is 0.785607 at the 1% confidence level. The model has good goodness-of-fit. The F statistic is
143.2981, and the corresponding p value is 0, indicating that the regression equation has passed the test on the
whole, and the independent variable has a high degree of explanation to the dependent variable.
In terms of the practical significance of the regression results of the model, firstly, the coefficient sign of
the variable GDP it is positive, indicating that the change of China's GDP will have an important positive impact
on the export of pharmaceutical products. Other things being equal, if China's GDP increases by 1%, China's
pharmaceutical exports will increase by 0.94%. The bigger China's economy means more pharmaceutical
products are produced in China, which boosts exports. Second, the coefficient symbol of the variable GDP jt and
is positive, which has a positive impact on the export volume of China's pharmaceutical products. That is, if
other conditions remain unchanged, the GDP of the importing country increases by 1%, the export volume of
China's pharmaceutical products will increase by 0.57%, indicating that the expansion of the economic scale of
the importing country will improve the demand structure of the importing country and increase the import
demand for China's pharmaceutical products. In terms of coefficient, China's GDP has a greater impact on the
export volume of China's pharmaceutical products than the GDP of importing countries, and China's economic
scale and supply capacity are more decisive to a certain extent. Thirdly, the coefficient of variable POPj is 0.12,
indicating that the demographic dividend of importing countries still has a positive impact on China's
pharmaceutical export trade. As a developing country with a large population in the world, India has a strong
potential demand for pharmaceutical products, and the export trade of pharmaceutical products from China to
India is also full of opportunities. Fourth, the coefficient of the variable DISij is negative, in line with
expectations. Geographic distance impedes China's export trade in pharmaceutical products. In other words, if
other conditions remain unchanged, every 1% decrease in the distance between China and its partner countries
will increase China's pharmaceutical exports by 0.67%. Therefore, the establishment of better infrastructure and
the minimization of transportation costs will provide a boost to pharmaceutical exports. At last. The dummy
variable LANij has a positive promoting effect on China's pharmaceutical export trade. English is very
influential in India, and English is one of the official languages of India. The language advantage of Indian
human resources makes the culture of India closer to multinational companies, and reduces the language and
cultural barriers in India's international cooperation. At the same time, many senior executives of Indian
pharmaceutical companies have overseas working and management background and professional managers
familiar with international business cooperation, which forms the comparative advantage of Indian
pharmaceutical trade. Especially for cross-border e-commerce, the most difficult problem is communication and
payment. As a cross-border e-commerce platform for the first batch of Indian drugs, the operation model of
"India's First Pharmacy" is reflected in the presence of a separate operation team for customers. For example, all
the customer service staff of the shopping mall for Chinese customers are Chinese nationals or proficient in
Chinese. This method effectively avoids the problem of communication and payment. Although the operation
cost has increased, the user feedback is the best.China and India should strengthen cultural and linguistic
exchanges and promote the development of medical trade.
3.2 Estimation of trade potential of Chinese pharmaceutical products exported to India
For the measurement of export trade potential, In this paper, the method of Liu Qingfeng and Jiang Shuzhu
(2002) is adopted to bring the data of explanatory variables over the years into the extended trade gravity model,
so as to obtain the simulated value of the export volume in the theoretical state. Then, the actual export volume
is divided by the simulated export volume, and the ratio obtained is the trade potential value of the export
volume. If the ratio is greater than or equal to 1.20, it is a "potential reshape ", indicating that the existing trade
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potential has been exhausted; if the ratio is between 0.80 and 1.20, it is a " potential development " type,
indicating that the potential of both sides of trade has not been fully exploited, and there is still room for further
expansion of bilateral trade relations. If the ratio is less than or equal to 0.80, it is a "huge potential", indicating
that there is a huge trade potential, and the possible factors that hinder the growth of export trade need to be
excluded. Accordingly, the parameter data of China and India from 2001 to 2018 were substituted into Equation
(2) to obtain the simulated value of China's pharmaceutical products export to India from 2001 to 2018, and then
the potential value of export trade was obtained. As shown in Figure 1, 2001-2018 China exports to India's
exports is greater than the actual simulation pharmaceutical products, and the ratio of the two is greater than or
equal to 1.20, the overall belongs to "potential reshape ".

Figure 1. Analog value, actual value and ratio chart of China's pharmaceutical exports to India
Data source: collated according to Eviews output

4.CONCLUSIONS AND SUGGESTION
4.1 Conclusion
First, through the empirical study on the explicit comparative advantage index (RCA) of trade between
China and India, it can be concluded that China has strong international competitiveness in 3001, 3002, 3005
and 3006 pharmaceutical products. India, on the other hand, has strong international competitiveness in 3004
and other pharmaceutical products. The differences between China and India further consolidate the foundation
of pharmaceutical trade cooperation, and the two countries urgently need to further strengthen economic and
trade cooperation and expand the trade scale.
Second, extended Trade Gravity Model was used to empirically test the significance of China's influence
factors on India's pharmaceutical exports. The regression analysis shows that the GDP of China and India, the
population and language of India promote the export of Chinese pharmaceutical products to India, while the
transportation cost represented by the bilateral distance hinders the development of the export trade of Chinese
pharmaceutical products to India.
Third, from the results of export trade potential analysis, China's export trade of pharmaceutical products to
India as a whole belongs to the “potential reshape” type. This indicates that China needs to develop a multi-level
and diversified new trade pattern while maintaining the existing development pattern of pharmaceutical trade.
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4.2 Suggestion
In the external environment of rising protectionism, sluggish world economy and shrinking global market,
uncertainties and destabilizing factors in global trade have increased significantly, which has made India's
diplomatic and military routes increasingly warlike and led to increased trade frictions between China and India.
However, in the face of the most serious pandemic of infectious diseases in the past century, the
fundamentals of China-India trade in pharmaceutical products remain sound in the long run. It is more urgent to
accelerate the cultivation of new competitive advantages in China-India pharmaceutical trade. Under the current
new development pattern of domestic cycle as the main body and domestic and international double cycle
mutual promotion, in order to promote the innovative development of pharmaceutical trade and promote the
joint construction of high-quality development of "One Belt And One Road", this paper puts forward the
following development suggestions:
4.2.1 For government
First, Governments should strengthen exchanges and cooperation. The government should take the "One
Belt And One Road" initiative as an opportunity to explore trade liberalization of important medical materials,
actively and steadily promote the construction of a "green channel" for goods, maintain the safe and smooth
operation of the global industrial chain and supply chain. We will promote high-quality "One Belt and One
Road" cooperation and work together to overcome the challenge of the epidemic. Secondly, the government
should increase the investment in the pharmaceutical industry, and improve the international competitiveness of
China's pharmaceutical products through scientific and technological innovation and digital transformation. The
government can fully rely on the Asian Infrastructure Investment Bank to expand China's infrastructure
investment in the "One Belt And One Road" countries such as India, promote the construction of the
Bangladesh-China-India-Myanmar Economic Corridor, strengthen the construction of digital infrastructure,
actively reduce the negative impact of distance factors on the trade of pharmaceutical products between the two
countries, and stimulate greater trade potential. Last but not least, we should promote medical culture and
people-to-people exchanges between China and India. We should actively cultivate talents proficient in the
languages, customs and economic and trade laws of both sides, further improve the quality of our language
services, improve the international universality of Chinese, use English as an effective communication tool, and
appropriately use Hindi to enhance feelings and cultural identity, facilitate orderly exchanges of personnel, and
reduce trade risks.
4.2.2 For companies
First, Chinese and Indian pharmaceutical companies should strengthen cooperation. Cooperation in the
field of medicine and health is an important part of the "One Belt and One Road" construction. Chinese
pharmaceutical enterprises should make full use of various preferential policies and international resources
under the "One Belt and One Road" initiative to improve the quality and growth of China-India pharmaceutical
cooperation, diversify the product structure of China-India pharmaceutical trade, and reduce the impact of
competition of homogenized pharmaceutical products. At the same time, Chinese pharmaceutical companies
should fully understand Indian customs, medical demand preferences and local laws and regulations, customize
sales in terms of pharmaceutical product grade, price, trademark and curative effect to expand the scale of
pharmaceutical trade. Secondly, enterprises should enhance the modernization level of the industrial chain and
supply chain, strengthen the innovation of pharmaceutical products. At the same time, in the production process
of pharmaceutical products, enterprises should strengthen supervision to ensure product quality. Finally, Indian
cross-border e-commerce enterprises should further reduce the cost of cross-border trade, improve the logistics
and distribution system of pharmaceutical products, improve the safety of cross-border pharmaceutical products,
conduct new media marketing and social media interaction on the clustering websites of consumers in their
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respective market segments, and create first-class consumption experience.
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